Drug intelligence / Profile preview

alisol g

Development stage: Preclinical
Modality: Small Molecules

Overview

Alisol G (25-anhydroalisol A) is a natural protostane-type triterpene isolated from the rhizomes of *Alisma orientalis* (Rhizoma Alismatis). It is primarily investigated as a research compound for its diverse pharmacological properties. Mechanistically, it has been shown to inhibit human carboxylesterase 2 (hCE2) and modulate several metabolic and signaling pathways, including the AMPK/ACC/SREBP-1c pathway for anti-obesity effects and the RARα-PPARγ-CD36 cascade for reducing hepatic lipid accumulation. Additionally, it exhibits anti-cancer activity by inactivating PI3K/Akt signaling in colorectal cancer cells and possesses antibacterial properties against Gram-positive bacteria. It is currently not approved for clinical use and is utilized only in preclinical research.

Other names: 25-anhydroalisol Aalisol G

Targets

CES2 (Carboxylesterase 2)

Beyond the preview

Go deeper on alisol g.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on alisol g.

Explore the full profile